StoneWi

StoneWise (Beijing StoneWise Technology Co., Ltd.) is an AI-driven drug discovery company founded in 2018 and headquartered in the Haidian District of Beijing, China. The company develops an advanced generative AI platform — MolVado — that accelerates small molecule drug design through multimodal 3D molecule generation, computational chemistry evaluation tools, and a physical compound library of over 26 million high-purity compounds. StoneWise integrates deep learning and geometric deep learning with medicinal chemistry expertise to compress the drug design-test-analyze-make (DMTA) cycle, reducing early-stage R&D costs. The company has raised $100 million in funding from investors including Hillhouse Investment, SIG Asia, Long Hill Capital, Xiang He Capital, and Linear Venture.